Myriad Genetics (MYGN) Misses Q4 EPS by 6c; Issues Weak Q1, FY17 Outlook
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Jefferies Remains Sidelined on Myriad Genetics (MYGN) Following 4Q
August 11, 2016 8:37 AM EDTJefferies maintained a Hold rating on Myriad Genetics (NASDAQ: MYGN), and cut the price target to $20.00 (from $34.00), following the company's 4Q earnings report. The company's weaker 4Q16 experience (-7%) and initial FY17 outlook for the HC segment (-7%) suggest pricing and... More
Barclays Downgrades Myriad Genetics (MYGN) to Equalweight
August 10, 2016 7:40 AM EDTBarclays downgraded Myriad Genetics (NASDAQ: MYGN) from Overweight to Equalweight with a price target of $24.00 (from $50.00).
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $29.46 yesterday.
... MoreMizuho Securities Cuts Price Target on Myriad Genetics (MYGN) to $22 Following 4Q and Guidance
August 10, 2016 7:19 AM EDTMizuho Securities maintained a Neutral rating on Myriad Genetics (NASDAQ: MYGN), and cut the price target to $22.00 (from $34.00), following the company's 4Q results and guidance. MYGN guided to 2017 revenues of $740mm-$760mm, versus consensus of $790mm, and EPS of $1.00-$1.10, versus consensus of $1.77.... More
Wells Fargo Downgrades Myriad Genetics (MYGN) to Market Perform
August 10, 2016 7:03 AM EDTWells Fargo downgraded Myriad Genetics (NASDAQ: MYGN) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $29.46 yesterday.
... MorePiper Jaffray Downgrades Myriad Genetics (MYGN) to Neutral
August 10, 2016 6:38 AM EDTPiper Jaffray downgraded Myriad Genetics (NASDAQ: MYGN) from Overweight to Neutral with a price target of $22.00 (from $47.00).
Analyst William Quirk commented, "Myriad's 4Q16 revenue declined 1.8% yoy to $186.5M, below our in line estimate of $187.7M. EPS of $0.36 was below our in line $0.37 estimate.... More
Myriad Genetics (MYGN) halted with news pending
August 9, 2016 4:00 PM EDTMyriad Genetics (NASDAQ: MYGN) halted with news pending.
... More